2009 Mid-Atlantic Bio Focuses on Industry Collaboration, Conference Concludes with Record High Attendance
Held at the Washington Convention Center on November 4-6, 2009 and co-hosted by Virginia Biotechnology Association (VaBIO), the Tech Council of Maryland/MdBio, and the Mid-Atlantic Venture Association (MAVA), 2009 Mid-Atlantic Bio attracted speakers who are preeminent leaders from the life sciences community. With record attendance, a sold-out conference hotel, and top-tier programming, Mid-Atlantic Bio has experienced continuous growth since its inception in 2005.
"Mid-Atlantic Bio has proven to be an essential forum for industry collaboration and information-sharing," said Julia A. Spicer, Executive Director of the Mid-Atlantic Venture Association, one of the three host associations. "This conference engenders dialogue among companies, investors, academia and policymakers, who are part of the global bioscience marketplace," she added.
With more than 850 attendees from 30 states and 10 countries, the annual Mid Atlantic Bio conference exceeded last year's registration figures and hosted participants from life science organizations, venture and investment firms, academic and research institutions, and government agencies.
Headlining the conference were plenary session speakers The Honorable Charles Boustany (R-LA); The Honorable Ben Cardin (D-MD); The Honorable Anna Eshoo (D-CA); Tony Zook, President, Medlmmune & CEO, AZ North America; H. Thomas Watkins, CEO, Human Genome Sciences; and R.J. Kirk, Senior Manager Director and CEO, Third Security and Intrexon.
The 2009 Mid-Atlantic Bio Symposium featured thought-leadership addressing the key areas of Science, Policy and Business/Finance. These three high level industry panels were presented to hundreds of representatives from biotech and device companies; research and academia institutions; private and public capital sources including private equity, venture, angel and biopharma investors; and government and embassy officials throughout the national capital region.
The Business Finance Panel focus was Financing Drug Development in Today's Environment: New Challenges and Opportunities; moderator: Amir Nashat, General Partner, Polaris Venture Partners. Public Policy Panel focus was The Regulatory Landscape in 2012: How will Washington affect the bioscience industry next year and beyond?; moderator: Sara Radcliffe, Executive Vice President Health, Biotechnology Industry Organization (BIO). Scientific Panel focus was How Deep Genetic Information is Transforming Biomedicine and Biobusiness; moderator: Brian A. Pollok, Ph.D., President, ATCC.
Forty-four exhibitors showcased products and services, and 12 science posters were on display featuring a variety of cutting-edge academic, federal laboratory and company research and development efforts providing commercial solutions. Twenty-four companies, emerging and later stage companies, presented before an audience of venture capitalists and industry professionals. The companies, at various stages of development, range from seed and early stages to later stage growth, and represented a cross-section of industry sectors. A variety of scientific, business and investor workshops and panels rounded out a full programming agenda.
Diamond sponsors for the 2009 conference included BioMaryland, the Commonwealth of Virginia and Human Genome Sciences. For a complete list of sponsors, visit www.midatlanticbio.org.